Overview
Dexmedetomidine on Tourniquet Induced -Systemic Effects
Status:
Completed
Completed
Trial end date:
2020-03-05
2020-03-05
Target enrollment:
0
0
Participant gender:
All
All
Summary
Eighty patients were randomly assigned to either control (CON) or dexmedetomidine (DEX) group. DEX group received a loading dose of 0.5 µg/ kg of intravenous dexmedetomidine over 10 minutes, followed by a continuous infusion of 0.5 µg/kg/h until completion of the surgery. CON group received the same calculated volume of normal saline. Pain outcomes, metabolic and coagulative changes after tourniquet application, and after tourniquet release were investigated.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Wonkwang University HospitalTreatments:
Dexmedetomidine
Criteria
Inclusion Criteria:- patients aged between 20 and 80 years, American Society of Anesthesiologists (ASA)
physical status class I-III, who were scheduled to undergo elective TKA
Exclusion Criteria:
- Patients with history of rheumatoid arthritis, diabetes mellitus, hepatic or renal
disease, allergy to drug being studied, heart block greater than first degree, left
ventricle ejection fraction < 55%, or chronic administration of anti-inflammatory
drugs, or opioids were excluded. Patients with tourniquet times of less than 60
minutes or longer than 150 minutes or with conversion to general anesthesia during
surgery